SAN
DIEGO, June 26, 2024 /PRNewswire/ -- The 2024 BIO
International Convention, the world's largest biotechnology event,
took place in San Diego,
USA, from June 3 to 6. This year's convention drew
biomedical investors and research experts worldwide. Over 1,500
exhibitors showcased their innovations to more than 19,500
attendees from 70 countries. The Taiwan Pavilion garnered
significant attention, holding over 400 meetings in four days and
highlighting Taiwan's rising
biotech industry.
Leading Taiwanese Pharmaceutical Companies' Capabilities
Showcased
The 2024 BIO International Convention's theme was "Time for
Science to Shine." The Taiwan
delegation, organized by the Ministry of Economic Affairs (MOEA)
Biotechnology and Pharmaceutical Industries Promotion Office
(BPIPO), in collaboration with the
Ministry of Health and Welfare, Ministry of Agriculture, National
Science and Technology Council, National Development Council,
Taipei City Government, and the National Biotechnology Research
Park. The delegation included over 80 companies and institutions,
with around 230 participants.
The delegation focused on new drug development, biotechnology,
CDMO (Contract Development and Manufacturing Organization), medical
devices, precision medicine, regenerative medicine, agricultural
biotechnology, and smart health. International buyers showed strong
interest in cancer treatment and CDMO, indicating significant
investment potential.
The Taiwan Pavilion featured a CDMO wall showcasing 10 leading
Taiwanese pharmaceutical companies' capabilities. This display
highlighted Taiwan's strengths in
intellectual property, regulatory frameworks, and policy support,
positioning Taiwan as an ideal
partner for international technical and manufacturing
collaborations.
Taiwan Pavilion Highlights Pharma Prowess
To strengthen international connections, the Taiwan Pavilion
hosted an opening reception and co-organized thematic conferences
on cell/gene therapy processes in the Asia-Pacific region and smart innovation
digital applications. These efforts aimed to accelerate industry
development and foster global integration.
The Taiwan Pavilion's exhibits featured new drug development
projects, including botanical drugs, small molecule drugs, and
protein drugs at various stages. They also showcased delivery
systems, personalized tumor avatars, organ-on-a-chip technology,
universal antibody platforms, cell therapy, and cell culture
technologies. Precision and smart medical solutions were
highlighted, such as interactive medical 3D imaging, cancer
diagnostics, AI physiological monitoring, rapid screening for
high-risk neurological diseases, targeted cancer therapies,
adhesive patch technology, early cancer screening, and 3D
pathological imaging.
Taiwan's biotech startups also
shone on the international stage, with five companies reaching the
final round of the BIO Start-Up Stadium competition and attracting
global investors' attention.
In her opening speech at the Taiwan Pavilion, Deputy
Director-General of the Industrial Development Bureau, Ministry of
Economic Affairs, Pei-Li Chen
emphasized the future trend of integrating cross-disciplinary
technologies for industrial development. She highlighted
Taiwan's strengths in information
and communication technology, comprehensive manufacturing supply
chain, and excellent clinical medical capabilities, positioning the
country for collaboration with other nations to develop superior
biomedical products and services.
Major Institutions and Global Partnerships at US BIO
Six major biomedical research institutions from Taiwan, including Academia Sinica, National
Health Research Institutes (NHRI), Development Center for
Biotechnology (DCB), Industrial Technology Research Institute's
Biomedical Technology and Device Research Laboratories, Medical and
Pharmaceutical Industry Technology and Development Center (PITDC),
and the Agricultural Technology Research Institute (ATRI),
showcased their technological achievements in agricultural
biotechnology, pharmaceuticals, and medical devices. The Taiwan
Bio-Industry Organization introduced the current state of
Taiwan's biotech industry and
collaboration opportunities at the Global Innovation Hub event,
promoting international partnerships.
During the exhibition, the Taiwan team visited the Phoenix biomedical cluster, including Mayo
Clinic's Barrow Neurological Institute, Translational Genomics
Research Institute (TGen), along with Rakuten Medical and Tanvex to explore opportunities for joint
drug development or production collaboration.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/taiwans-biotech-innovations-draw-international-attention-at-bio-2024-302183496.html
SOURCE BPIPO